The stock of Citius Pharmaceuticals Inc (CTXR) has seen a -8.84% decrease in the past week, with a 19.25% gain in the past month, and a 16.42% flourish in the past quarter. The volatility ratio for the week is 9.50%, and the volatility levels for the past 30 days are at 9.15% for CTXR. The simple moving average for the past 20 days is 7.64% for CTXR’s stock, with a 6.64% simple moving average for the past 200 days.
Is It Worth Investing in Citius Pharmaceuticals Inc (NASDAQ: CTXR) Right Now?
The 36-month beta value for CTXR is also noteworthy at 1.50. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for CTXR is 146.79M, and at present, short sellers hold a 8.30% of that float. The average trading volume of CTXR on April 10, 2024 was 732.75K shares.
CTXR) stock’s latest price update
The stock of Citius Pharmaceuticals Inc (NASDAQ: CTXR) has decreased by -7.36 when compared to last closing price of 0.96.Despite this, the company has seen a loss of -8.84% in its stock price over the last five trading days. PRNewsWire reported 2024-02-23 that CRANFORD, N.J., Feb. 23, 2024 /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced its participation in two upcoming investor conferences.
Analysts’ Opinion of CTXR
Many brokerage firms have already submitted their reports for CTXR stocks, with Maxim Group repeating the rating for CTXR by listing it as a “Buy.” The predicted price for CTXR in the upcoming period, according to Maxim Group is $4 based on the research report published on November 30, 2021 of the previous year 2021.
CTXR Trading at 17.46% from the 50-Day Moving Average
After a stumble in the market that brought CTXR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -47.94% of loss for the given period.
Volatility was left at 9.15%, however, over the last 30 days, the volatility rate increased by 9.50%, as shares surge +23.65% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +30.89% upper at present.
During the last 5 trading sessions, CTXR fell by -8.84%, which changed the moving average for the period of 200-days by -31.52% in comparison to the 20-day moving average, which settled at $0.8356. In addition, Citius Pharmaceuticals Inc saw 17.69% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for CTXR
The total capital return value is set at -0.42. Equity return is now at value -41.24, with -36.52 for asset returns.
Based on Citius Pharmaceuticals Inc (CTXR), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -70.87. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -10.22.
Currently, EBITDA for the company is -36.54 million with net debt to EBITDA at 0.52. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.06.
Conclusion
In summary, Citius Pharmaceuticals Inc (CTXR) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
